Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment
Journal of Cardiovascular Pharmacology and Therapeutics · 2025
DOI: 10.1177/10742484251361059 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, 2025. Verfasst von Zeyu Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Third Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Atorvastatin, Ultrasonography, Interventional, Coronary Artery Disease, Cholesterol, LDL. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Bureau of Nanchang Municipality.
Abstract (Originalsprache)
Background
While PCSK9 inhibition has proven safe and effective, there is limited research on using intravascular ultrasound (IVUS) to assess the impact of atorvastatin combined with PCSK9 inhibitors on borderline coronary lesions.
Methods
From June 2022 to June 2025, a detailed analysis of biochemical markers, coronary angiography (CAG), and IVUS was conducted on 69 patients with borderline coronary lesions after different treatments.
Results
Of the 69 patients enrolled, 60 completed the 48-week study. All groups showed significant low-density lipoprotein cholesterol (LDL-C) reductions, with Group C (Alirocumab + Atorvastatin) having the largest decrease from 3.64 to 1.48 ( P < .001). At 48 weeks, arterial lumen volumes increased in all groups, but Group C's was significantly larger than Groups A (Alirocumab + placebo) and B (Atorvastatin + placebo) ( P = .038). Group C also had a greater reduction in plaque volume compared to Groups A and B ( P = .041).
Conclusion
Alirocumab and Atorvastatin together significantly lowered LDL-C levels and improved the vascular environment, notably reversing plaque in patients with borderline coronary lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Third Affiliated Hospital of Nanchang University, Nanchang, China.
ORCID-Profile: Zeyu Xu
Förderung
- Science and Technology Bureau of Nanchang Municipality
Zitieren
APA
Xu, Z., Fang, Y., Peng, Y., Zhang, C., & Zheng, C. (2025). Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/10742484251361059
Vancouver
Xu Z, Fang Y, Peng Y, Zhang C, Zheng C. Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment. Journal of Cardiovascular Pharmacology and Therapeutics. 2025. doi:10.1177/10742484251361059
BibTeX
@article{Xu2025,
author = {Xu, Zeyu and Fang, Yi and Peng, Yong and Zhang, Chunhua and Zheng, Chunhua},
title = {Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment},
journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
year = {2025},
doi = {10.1177/10742484251361059}
}
EUVIMED